Nicholas contributes health policy and scientific expertise to the Margolis Center’s biomedical innovation and evidence development portfolio. Nicholas engages collaborative research and convening activities with the Center for Drug Evaluation and Research (CDER) at the U.S. FDA to advance and promote regulatory science and the more efficient development of safe and effective drugs for patients in need. Nicholas also contributes to projects that advance policy to incentivize the development and stewardship of priority antibiotics to combat antimicrobial resistance.
Nicholas is broadly interested in the design and implementation of policy that supports the effectiveness and continued evolution of evidence-based practice, with particular interest in medical innovation and primary care. Nicholas is a pharmacologist turned public health professional and is adept in evaluating the components of complex systems and communicating detailed messages to stakeholders across the healthcare landscape, from policy-makers and regulators to care-providers and patients.
MPH, Boston University School of Public Health
MA, Boston University School of Medicine
BS, The Ohio State University